Breast Cancer
Conditions
Keywords
Pyrotinib, Lapatinib, Vinorelbine
Brief summary
Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine
Detailed description
This is a retrospective study aiming to explore the efficacy and safety of Pyrotinib plus Vinorelbine versus Lapatinib plus Capecitabine in patients with previously treated HER2-positive metastatic breast cancer.
Interventions
None listed
Sponsors
Fudan University
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* HER2+ MBC patients scored +3 by immunohistochemical (IHC) analysis or scored +2 and the result of fluorescence in situ hybridization was positive. * Patients were previously treated with trastuzumab in the advanced setting and a taxane in any setting. * Patients received lapatinib (750-1,250 mg/day) plus capecitabine (1,500-2,000 mg/m2) or pyrotinib (320-400 mg/day) plus vinorelbine (25mg/ m2 intravenously or 60 mg/m2 orally on days 1 and 8 per 21 days) for at least one cycle, starting from Jun 2015 to Jan 2021. * Patients had complete medical records. All data were retrospectively collected from medical records of individual institutions.
Exclusion criteria
* Incomplete medical history
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PFS | 6 weeks | Progression free survival |
Secondary
| Measure | Time frame |
|---|---|
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | 6 weeks |
Countries
China
Outcome results
None listed